“Porem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.”
Martin Babler served as Principia’s Chief Executive Officer from 2011 and as President and Chief Executive Officer from 2019 until Sanofi’s $3.7 billion acquisition in 2020. From 2007 to 2011, Mr. Babler served as President and Chief Executive Officer of Talima Therapeutics. From 1998 to 2007, Mr. Babler held several positions at Genentech, most notably as Vice President, Immunology Sales and Marketing. While at Genentech he also helped to build and led the Commercial Development organization and led the Cardiovascular Marketing organization. From 1991 to 1998, Mr. Babler was employed at Eli Lilly and Company in sales management, global marketing, and business development.
Martin Babler presently serves on the Emerging Companies Section and Health Section Governing Boards of the Biotechnology Innovation Organization (BIO) and on the Board of Directors of Neoleukin Therapeutics. Mr. Babler received a Swiss Federal Diploma in Pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.
